NASDAQ:IPCI - IntelliPharmaCeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.41 +0.01 (+2.50 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.40
Today's Range$0.40 - $0.42
52-Week Range$0.32 - $2.92
Volume234,200 shs
Average Volume333,863 shs
Market Capitalization$17.42 million
P/E Ratio-1.45
Dividend YieldN/A
Beta1.31

About IntelliPharmaCeutics (NASDAQ:IPCI)

IntelliPharmaCeutics logoIntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Receive IPCI News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001

Debt

Debt-to-Equity RatioN/A
Current Ratio0.29
Quick Ratio0.25

Price-To-Earnings

Trailing P/E Ratio-1.45
Forward P/E Ratio-4.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.51 million
Price / Sales3.24
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book41.00

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-8,850,000.00
Net Margins-217.52%
Return on Equity-2,811.75%
Return on Assets-147.15%

Miscellaneous

Employees62
Outstanding Shares43,540,000

IntelliPharmaCeutics (NASDAQ:IPCI) Frequently Asked Questions

What is IntelliPharmaCeutics' stock symbol?

IntelliPharmaCeutics trades on the NASDAQ under the ticker symbol "IPCI."

How were IntelliPharmaCeutics' earnings last quarter?

IntelliPharmaCeutics (NASDAQ:IPCI) posted its quarterly earnings results on Thursday, October, 13th. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm earned $0.56 million during the quarter, compared to analysts' expectations of $0.50 million. IntelliPharmaCeutics had a negative return on equity of 2,811.75% and a negative net margin of 217.52%. View IntelliPharmaCeutics' Earnings History.

When is IntelliPharmaCeutics' next earnings date?

IntelliPharmaCeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for IntelliPharmaCeutics.

What price target have analysts set for IPCI?

3 Wall Street analysts have issued twelve-month target prices for IntelliPharmaCeutics' shares. Their forecasts range from $2.00 to $3.10. On average, they anticipate IntelliPharmaCeutics' stock price to reach $2.70 in the next twelve months. View Analyst Ratings for IntelliPharmaCeutics.

What are Wall Street analysts saying about IntelliPharmaCeutics stock?

Here are some recent quotes from research analysts about IntelliPharmaCeutics stock:
  • 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (5/8/2018)
  • 2. Maxim Group analysts commented, "1Q18 revenues were $0.3M, down from $1.1M in 4Q17 (Nov. YE). The decline owes largely to declining generic Focalin sales, citing pricing pressures in the US generics market. IPCI recently raised $4.5M through an equity financing, which extends the runway into 3Q18. However, we believe that over time the generics business for IPCI will continue to grow and provide revenue that helps offset cash burn associated with key programs: Abuse deterrent Oxycodone and PODRAS (preventing overdose); we view both programs as the long-term drivers of the company." (4/18/2018)

Who are some of IntelliPharmaCeutics' key competitors?

Who are IntelliPharmaCeutics' key executives?

IntelliPharmaCeutics' management team includes the folowing people:
  • Dr. Isa Odidi Ph.D., MBA, Co-Founder, Chairman, CEO & Co-Chief Scientist (Age 60)
  • Dr. Amina Odidi, Pres, COO, Co-Chief Scientist & Director (Age 58)
  • Mr. Andrew P. Patient B.Acc, C.A., Chief Financial Officer (Age 47)
  • Dr. Patrick N. Yat, Vice-Pres of Chemistry & Analytical Services (Age 60)
  • Mr. Christian Akyempon, VP of Commercial Operations

Has IntelliPharmaCeutics been receiving favorable news coverage?

News coverage about IPCI stock has trended somewhat positive on Friday, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IntelliPharmaCeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 46.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are IntelliPharmaCeutics' major shareholders?

IntelliPharmaCeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include ANSON FUNDS MANAGEMENT LP (7.20%) and Anson Funds Management LP (4.89%). View Institutional Ownership Trends for IntelliPharmaCeutics.

Which institutional investors are buying IntelliPharmaCeutics stock?

IPCI stock was purchased by a variety of institutional investors in the last quarter, including Anson Funds Management LP. View Insider Buying and Selling for IntelliPharmaCeutics.

How do I buy shares of IntelliPharmaCeutics?

Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IntelliPharmaCeutics' stock price today?

One share of IPCI stock can currently be purchased for approximately $0.41.

How big of a company is IntelliPharmaCeutics?

IntelliPharmaCeutics has a market capitalization of $17.42 million and generates $5.51 million in revenue each year. The company earns $-8,850,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. IntelliPharmaCeutics employs 62 workers across the globe.

How can I contact IntelliPharmaCeutics?

IntelliPharmaCeutics' mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at investors[email protected]


MarketBeat Community Rating for IntelliPharmaCeutics (IPCI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IntelliPharmaCeutics (NASDAQ:IPCI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for IntelliPharmaCeutics in the last 12 months. Their average twelve-month price target is $2.70, suggesting that the stock has a possible upside of 558.54%. The high price target for IPCI is $3.10 and the low price target for IPCI is $2.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.252.33
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.70$2.70$2.5250$2.3667
Price Target Upside: 558.54% upside409.43% upside227.92% upside134.32% upside

IntelliPharmaCeutics (NASDAQ:IPCI) Consensus Price Target History

Price Target History for IntelliPharmaCeutics (NASDAQ:IPCI)

IntelliPharmaCeutics (NASDAQ:IPCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018Maxim GroupReiterated RatingHoldLowView Rating Details
3/5/2018HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
9/26/2017MackieUpgradeHold$1.00 ➝ $3.10MediumView Rating Details
4/18/2017AegisReiterated RatingHold$2.00LowView Rating Details
10/17/2016Brean CapitalSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

IntelliPharmaCeutics (NASDAQ:IPCI) Earnings History and Estimates Chart

Earnings by Quarter for IntelliPharmaCeutics (NASDAQ:IPCI)

IntelliPharmaCeutics (NASDAQ:IPCI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.1 EPS
Next Year EPS Consensus Estimate: $0.05 EPS

IntelliPharmaCeutics (NASDAQ IPCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018        
2/16/2018Q4 2017($0.07)($0.08)$1.32 million$1.08 millionViewN/AView Earnings Details
10/10/2017Q3 2017($0.04)($0.08)$2.45 million$1.19 millionViewN/AView Earnings Details
7/11/2017Q2 2017($0.05)($0.06)$1.86 million$2.00 millionViewN/AView Earnings Details
4/11/2017Q1 2017($0.08)($0.07)$2.30 million$1.24 millionViewN/AView Earnings Details
2/10/2017Q4 2016($0.06)($0.14)$0.60 million$0.57 millionViewN/AView Earnings Details
10/13/2016Q316($0.07)($0.07)$0.50 million$0.56 millionViewN/AView Earnings Details
7/13/2016Q216($0.09)($0.08)$0.80 million$0.56 millionViewN/AView Earnings Details
4/14/2016Q1($0.07)($0.09)$0.70 million$0.57 millionViewN/AView Earnings Details
2/26/2016Q4 2015($0.06)($0.13)$1.20 million$0.85 millionViewN/AView Earnings Details
10/9/2015Q315($0.05)($0.08)$1.30 million$0.84 millionViewN/AView Earnings Details
7/13/2015Q215($0.05)($0.06)$1.20 million$1.27 millionViewN/AView Earnings Details
4/14/2015Q1 2015($0.08)($0.04)$1.20 million$1.14 millionViewN/AView Earnings Details
2/23/2015Q4 2014($0.07)($0.06)$1.40 million$1.54 millionViewN/AView Earnings Details
10/15/2014Q3($0.05)($0.07)$2.40 million$1.07 millionViewN/AView Earnings Details
7/7/2014Q2 2014($0.14)$2.00 million$1.48 millionViewN/AView Earnings Details
4/14/2014Q114$0.11$0.09$4.49 million$4.70 millionViewN/AView Earnings Details
2/18/2014($0.08)($0.31)$4.25 million$1.53 millionViewN/AView Earnings Details
10/1/2013Q3 2013($0.10)($0.10)ViewN/AView Earnings Details
7/2/2013Q2 2013($0.15)($0.10)ViewN/AView Earnings Details
4/3/2013Q113($0.12)($0.07)ViewN/AView Earnings Details
1/31/2013Q4 2012($0.12)($0.14)ViewN/AView Earnings Details
10/2/2012Q3 2012($0.12)($0.11)ViewN/AView Earnings Details
7/3/2012Q2 2012($0.15)($0.13)ViewN/AView Earnings Details
5/10/2012Q4 2011$0.03ViewN/AView Earnings Details
4/12/2012Q1 2012($0.13)($0.12)ViewN/AView Earnings Details
10/7/2011Q3 2011($0.14)($0.09)ViewN/AView Earnings Details
7/5/2011Q2 2011($0.13)($0.16)ViewN/AView Earnings Details
4/14/2011Q1 2011($0.15)($0.12)ViewN/AView Earnings Details
10/15/2010Q3 2010($0.20)ViewN/AView Earnings Details
7/14/2010Q2 2010($0.04)ViewN/AView Earnings Details
4/13/2010Q1 2010($0.13)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.13)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.01)ViewN/AView Earnings Details
7/14/2009Q2 2009($0.27)ViewN/AView Earnings Details
4/13/2009Q1 2009($0.59)ViewN/AView Earnings Details
2/27/2009Q4 2008($0.39)ViewN/AView Earnings Details
10/15/2008Q3 2008($1.23)ViewN/AView Earnings Details
7/9/2008Q2 2008($5.00)ViewN/AView Earnings Details
4/3/2008Q1 2008($3.64)ViewN/AView Earnings Details
1/16/2008Q4 2007($3.94)($4.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

IntelliPharmaCeutics (NASDAQ:IPCI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

IntelliPharmaCeutics (NASDAQ IPCI) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 25.56%
Insider Trading History for IntelliPharmaCeutics (NASDAQ:IPCI)
Institutional Ownership by Quarter for IntelliPharmaCeutics (NASDAQ:IPCI)

IntelliPharmaCeutics (NASDAQ IPCI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

IntelliPharmaCeutics (NASDAQ IPCI) News Headlines

Source:
DateHeadline
BRIEF-Intellipharmaceutics Received Notice From Nasdaq Hearings PanelBRIEF-Intellipharmaceutics Received Notice From Nasdaq Hearings Panel
www.reuters.com - May 23 at 9:28 AM
Nasdaq Hearings Panel Grants Intellipharmaceutics Request for Continued ListingNasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing
finance.yahoo.com - May 22 at 4:09 PM
Intellipharmaceutics Reports Director Election ResultsIntellipharmaceutics Reports Director Election Results
finance.yahoo.com - May 16 at 10:25 AM
Intellipharmaceutics Bounces on New Oxycodone ER StudiesIntellipharmaceutics Bounces on New Oxycodone ER Studies
www.baystreet.ca - May 8 at 4:05 PM
Form 6-K Intellipharmaceutics For: May 08Form 6-K Intellipharmaceutics For: May 08
www.streetinsider.com - May 8 at 9:50 AM
Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ERIntellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER
finance.yahoo.com - May 8 at 9:50 AM
IntelliPharmaCeutics (IPCI) Cut to "Hold" at Zacks Investment ResearchIntelliPharmaCeutics (IPCI) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 7:04 AM
Wired News – Asterias Biotherapeutics: Clinical Grade Lot Released to Support Dosing of Subjects in First Clinical Study of AST-VAC2 in Non-Small Cell Lung CancerWired News – Asterias Biotherapeutics: Clinical Grade Lot Released to Support Dosing of Subjects in First Clinical Study of AST-VAC2 in Non-Small Cell Lung Cancer
finance.yahoo.com - April 27 at 10:37 AM
Intellipharmaceutics Files Appeal to Nasdaq Delisting DeterminationIntellipharmaceutics Files Appeal to Nasdaq Delisting Determination
finance.yahoo.com - April 27 at 10:37 AM
IntelliPharmaCeutics Intl (IPCI) Upgraded by Zacks Investment Research to BuyIntelliPharmaCeutics Intl (IPCI) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 25 at 11:30 AM
Intellipharmaceutics Receives Delisting Determination from NASDAQ Staff; Company to Request HearingIntellipharmaceutics Receives Delisting Determination from NASDAQ Staff; Company to Request Hearing
finance.yahoo.com - April 24 at 9:56 AM
IntelliPharmaCeutics Intl (IPCI) Stock Rating Lowered by Zacks Investment ResearchIntelliPharmaCeutics Intl (IPCI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 9:40 PM
IntelliPharmaCeutics Intls (IPCI) Hold Rating Reaffirmed at Maxim GroupIntelliPharmaCeutics Intl's (IPCI) Hold Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - April 18 at 4:13 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2018 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2018 Results
www.finanznachrichten.de - April 17 at 10:03 AM
Intellipharmaceutics Announces First Quarter 2018 ResultsIntellipharmaceutics Announces First Quarter 2018 Results
finance.yahoo.com - April 17 at 10:02 AM
IntelliPharmaCeutics Intl (IPCI) Downgraded by ValuEngine to "Sell"IntelliPharmaCeutics Intl (IPCI) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 15 at 10:59 AM
IntelliPharmaCeutics Intl (IPCI) Stock Rating Upgraded by Zacks Investment ResearchIntelliPharmaCeutics Intl (IPCI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Rating of "Hold" from BrokeragesIntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 4 at 11:37 AM
IntelliPharmaCeutics Intl (IPCI) Upgraded to "Hold" at Zacks Investment ResearchIntelliPharmaCeutics Intl (IPCI) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM
Zacks Investment Research Lowers IntelliPharmaCeutics Intl (IPCI) to SellZacks Investment Research Lowers IntelliPharmaCeutics Intl (IPCI) to Sell
www.americanbankingnews.com - March 27 at 9:44 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Closing of US$1.8 Million FinancingIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Closing of US$1.8 Million Financing
www.finanznachrichten.de - March 22 at 9:50 AM
Intellipharmaceutics Announces Closing of US$1.8 Million FinancingIntellipharmaceutics Announces Closing of US$1.8 Million Financing
finance.yahoo.com - March 22 at 9:50 AM
Intellipharmaceutics (IPCI) Announces $1.8 Million Registered Direct OfferingIntellipharmaceutics (IPCI) Announces $1.8 Million Registered Direct Offering
www.streetinsider.com - March 20 at 9:50 AM
Intellipharmaceutics (IPCI) Announces $1.8 Million Registered Direct Offering - StreetInsider.comIntellipharmaceutics (IPCI) Announces $1.8 Million Registered Direct Offering - StreetInsider.com
www.streetinsider.com - March 19 at 4:14 PM
Intellipharmaceutics Announces Closing of US$3.5 Million FinancingIntellipharmaceutics Announces Closing of US$3.5 Million Financing
finance.yahoo.com - March 17 at 10:50 AM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from BrokeragesIntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 10 at 9:44 AM
HC Wainwright Analysts Give IntelliPharmaCeutics Intl (IPCI) a $3.00 Price TargetHC Wainwright Analysts Give IntelliPharmaCeutics Intl (IPCI) a $3.00 Price Target
www.americanbankingnews.com - March 5 at 2:58 PM
Head-To-Head Contrast: IntelliPharmaCeutics Intl (IPCI) and Neuralstem (CUR)Head-To-Head Contrast: IntelliPharmaCeutics Intl (IPCI) and Neuralstem (CUR)
www.americanbankingnews.com - March 2 at 12:08 PM
Analyzing Theravance Biopharma (TBPH) and IntelliPharmaCeutics Intl (IPCI)Analyzing Theravance Biopharma (TBPH) and IntelliPharmaCeutics Intl (IPCI)
www.americanbankingnews.com - February 23 at 11:12 PM
Maxim Group Lowers IntelliPharmaCeutics Intl (IPCI) to HoldMaxim Group Lowers IntelliPharmaCeutics Intl (IPCI) to Hold
www.americanbankingnews.com - February 16 at 3:34 PM
Intellipharmaceutics Announces Fiscal Year 2017 ResultsIntellipharmaceutics Announces Fiscal Year 2017 Results
finance.yahoo.com - February 16 at 9:29 AM
 Brokerages Anticipate IntelliPharmaCeutics Intl Inc (IPCI) to Post -$0.07 Earnings Per Share Brokerages Anticipate IntelliPharmaCeutics Intl Inc (IPCI) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - February 14 at 11:16 PM
Intellipharmaceutics Sets Earnings Release Date for Year End 2017 ResultsIntellipharmaceutics Sets Earnings Release Date for Year End 2017 Results
finance.yahoo.com - February 14 at 6:02 AM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from AnalystsIntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 13 at 9:22 AM
IntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC WainwrightIntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 12 at 7:52 PM
Maxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price TargetMaxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price Target
www.americanbankingnews.com - February 9 at 9:30 PM
Intellipharmaceutics (IPCI) Announced Completed Meetings with ... - StreetInsider.comIntellipharmaceutics (IPCI) Announced Completed Meetings with ... - StreetInsider.com
www.streetinsider.com - February 9 at 3:27 PM
Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development ProgramIntellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program
finance.yahoo.com - February 9 at 3:27 PM
Reviewing IntelliPharmaCeutics Intl (IPCI) and Marinus Pharmaceuticals (MRNS)Reviewing IntelliPharmaCeutics Intl (IPCI) and Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - February 3 at 5:14 PM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $1.32 MillionIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $1.32 Million
www.americanbankingnews.com - January 30 at 1:52 AM
 Analysts Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share Analysts Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - January 28 at 11:10 PM
Intellipharmaceutics Provides Operational Update - GlobeNewswire (press release)Intellipharmaceutics Provides Operational Update - GlobeNewswire (press release)
globenewswire.com - January 26 at 5:53 AM
Intellipharmaceutics (IPCI) Announces Operational Update - StreetInsider.comIntellipharmaceutics (IPCI) Announces Operational Update - StreetInsider.com
www.streetinsider.com - January 24 at 3:23 PM
IntelliPharmaCeutics Intl (IPCI) Coverage Initiated at HC WainwrightIntelliPharmaCeutics Intl (IPCI) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - January 20 at 7:38 PM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Average Recommendation of "Hold" from BrokeragesIntelliPharmaCeutics Intl Inc (IPCI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 10:32 AM
$1.75 Million in Sales Expected for IntelliPharmaCeutics Intl Inc (IPCI) This Quarter$1.75 Million in Sales Expected for IntelliPharmaCeutics Intl Inc (IPCI) This Quarter
www.americanbankingnews.com - January 14 at 2:04 PM
AzurRx BioPharma (AZRX) versus IntelliPharmaCeutics Intl (IPCI) Head to Head ReviewAzurRx BioPharma (AZRX) versus IntelliPharmaCeutics Intl (IPCI) Head to Head Review
www.americanbankingnews.com - January 13 at 5:54 AM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Earnings of -$0.08 Per ShareIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - January 12 at 1:18 AM
Teligent (TLGT) & IntelliPharmaCeutics Intl (IPCI) Head to Head ContrastTeligent (TLGT) & IntelliPharmaCeutics Intl (IPCI) Head to Head Contrast
www.americanbankingnews.com - January 10 at 5:10 AM
 Brokerages Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share Brokerages Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - December 26 at 1:37 PM

SEC Filings

IntelliPharmaCeutics (NASDAQ:IPCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IntelliPharmaCeutics (NASDAQ:IPCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IntelliPharmaCeutics (NASDAQ IPCI) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.